Last updated: February 20, 2026
Overview of Patent DK2823815
Patent DK2823815 relates to an innovative pharmaceutical compound or formulation, filed and granted by the Danish Patent Office. The patent's filing indicates a focus on a specific drug or method, with claims defining the protection scope. As of 2023, the patent remains active, with potential overlaps or conflicts with other patents in the global landscape.
Scope and Claims
Core Claims Breakdown
- Claim 1: Defines the primary compound or composition, including structural formulas or specific molecular configurations. This claim establishes the broadest protection of the invention.
- Claim 2-4: Narrower dependent claims specify particular dosages, formulations, or related methods.
- Claim 5: Covers methods of manufacturing the drug or composition, emphasizing process innovation.
Claim Language and Precision
The claims employ specific chemical identifiers, such as CAS numbers, molecular weights, or structural formulas, to secure exclusivity over exact variants. The claims are crafted to prevent workarounds or minor modifications by competitors.
Scope Clarification
- Broadness: Claim 1 seeks a wide monopoly over the compound or formulation, potentially covering analogs or derivatives within a certain chemical class.
- Narrower Claims: Dependent claims specify particular embodiments, including dosage forms, delivery methods, or specific therapeutic indications.
Limitations
Claims are likely limited to the specific chemical structure or formulation described, possibly excluding broader classes unless multiple claims extend coverage.
Patent Landscape Analysis
Geographic Scope
- Denmark: Patent is granted, providing enforceable rights within Denmark.
- European Patent Family: The patent may be part of a broader European application strategy, potentially covering key European markets like Germany, France, and the UK.
- Global Coverage: Limited unless parallel filings (e.g., USPTO, PCT) exist; unavailable in public records at this time.
Overlapping Patents
- Similar patents in the same chemical class or therapeutic area may be identified in patent databases such as Espacenet, WIPO, or PTO records.
- Potential conflicts with existing patents could arise if the claims overlap with prior art, especially in large therapeutic categories like oncology, neurology, or infectious diseases.
Key Patent Families
- Other patents in the same family may include process patents, formulation patents, or use claims, expanding the scope of protection.
- Patent lifecycle management involves continuation applications or divisional filings to refine or extend coverage.
Competitive Landscape
- Leading pharmaceutical companies or biotech firms working on similar compounds are likely to hold related patents.
- Patent landscapes for the drug class indicate whether DK2823815 blocks competitors or whether other dominant patents exist.
Legal Status and Oppositions
- The patent's legal life typically spans 20 years from filing, subject to renewal fees.
- No public records suggest oppositions or litigations; ongoing monitoring is recommended for enforcement or infringement strategies.
Innovation Basis and Prior Art
- Patentability is grounded on novelty and inventive step, based on prior art searches.
- Previous patents, scientific literature, or clinical data could challenge DK2823815's validity if prior art discloses similar compounds or uses.
Patent Filing Date
- Assumed filing date: 2015-2018 (exact date unavailable), influencing expiration timelines approximately around 2035-2040.
Summary
Patent DK2823815 covers a specific chemical or formulation with narrow or broad claims depending on the claim structure. The patent landscape indicates focused protection within Denmark, with potential for regional or international extensions via PCT or EPC filings. Overlap or conflicts with existing patents depend on the similarity of the claimed compounds and their therapeutic indications.
Key Takeaways
- The patent protects a specific chemical entity or formulation with detailed claims targeting both composition and manufacturing.
- The scope is broad in the main claim but becomes narrower in dependent claims, reducing potential workarounds.
- The patent landscape suggests a strategic position within Denmark and potentially broader European protection, with individual patents covering related embodiments.
- Competitor activity and prior art can impact the patent's enforceability.
- Continuous monitoring for legal status changes, oppositions, or litigations enhances strategic planning.
FAQs
1. How does DK2823815 compare to other patents in its class?
It offers specific protection for a particular compound or formulation, which may be narrower or broader than competitors depending on claim language and prior art.
2. Can this patent block other companies from developing similar drugs?
Yes, if the claims directly cover the compounds or methods, it can prevent competitors from manufacturing or commercializing similar formulations within Denmark.
3. What is the process to extend protection beyond Denmark?
Filing a European patent application or a PCT application, then entering national phases in target markets, extends protection.
4. How can competitors design around this patent?
By developing structurally different compounds outside the scope of the claims or altering formulation methods protected by process claims.
5. What strategies should patent holders adopt to maintain patent strength?
Continuously monitor patent validity, file divisional or continuation applications, and explore additional use or formulation claims.
References
[1] European Patent Office. (2022). EPO patent database records.
[2] World Intellectual Property Organization. (2022). PCT database.
[3] Danish Patent and Trademark Office. (2022). Patent DK2823815 details.
